BRISTOL-MYERS SQUIBB CO (BMY)
US1101221083 - Common Stock
Overall BMY gets a fundamental rating of 5 out of 10. We evaluated BMY against 198 industry peers in the Pharmaceuticals industry. While BMY has a great profitability rating, there are some minor concerns on its financial health. BMY is valued quite cheap, but it does not seem to be growing. Finally BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year BMY was profitable.
In the past year BMY had a positive cash flow from operations.
Of the past 5 years BMY 4 years were profitable.
BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMY has a Return On Assets of 8.43%. This is amongst the best in the industry. BMY outperforms 92.31% of its industry peers.
The Return On Equity of BMY (27.27%) is better than 94.36% of its industry peers.
BMY has a Return On Invested Capital of 13.17%. This is amongst the best in the industry. BMY outperforms 92.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BMY is below the industry average of 16.40%.
The 3 year average ROIC (12.66%) for BMY is below the current ROIC(13.17%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.43% | ||
| ROE | 27.27% | ||
| ROIC | 13.17% |
ROA(3y)7.12%
ROA(5y)3.28%
ROE(3y)22.36%
ROE(5y)9.98%
ROIC(3y)12.66%
ROIC(5y)9.89%
1.3 Margins
BMY's Profit Margin of 17.83% is amongst the best of the industry. BMY outperforms 92.31% of its industry peers.
BMY's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 24.11%, BMY belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
BMY's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 76.44%, BMY belongs to the top of the industry, outperforming 81.54% of the companies in the same industry.
In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.11% | ||
| PM (TTM) | 17.83% | ||
| GM | 76.44% |
OM growth 3Y19.63%
OM growth 5Y-7.09%
PM growth 3YN/A
PM growth 5Y-3.95%
GM growth 3Y1.17%
GM growth 5Y1.35%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BMY is creating some value.
The number of shares outstanding for BMY has been reduced compared to 1 year ago.
Compared to 5 years ago, BMY has more shares outstanding
Compared to 1 year ago, BMY has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.30 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BMY (2.30) is better than 71.79% of its industry peers.
BMY has a debt to FCF ratio of 3.14. This is a good value and a sign of high solvency as BMY would need 3.14 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.14, BMY belongs to the top of the industry, outperforming 90.77% of the companies in the same industry.
BMY has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
BMY has a Debt to Equity ratio of 1.25. This is in the lower half of the industry: BMY underperforms 76.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 3.14 | ||
| Altman-Z | 2.3 |
ROIC/WACC1.73
WACC7.63%
2.3 Liquidity
A Current Ratio of 1.43 indicates that BMY should not have too much problems paying its short term obligations.
The Current ratio of BMY (1.43) is worse than 76.92% of its industry peers.
A Quick Ratio of 1.31 indicates that BMY should not have too much problems paying its short term obligations.
BMY has a Quick ratio of 1.31. This is in the lower half of the industry: BMY underperforms 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.31 |
3. Growth
3.1 Past
BMY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.86%.
Measured over the past years, BMY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.51% on average per year.
The Revenue has decreased by -2.50% in the past year.
Measured over the past years, BMY shows a quite strong growth in Revenue. The Revenue has been growing by 14.81% on average per year.
EPS 1Y (TTM)-3.86%
EPS 3Y5.21%
EPS 5Y13.51%
EPS growth Q2Q-6.59%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y1.91%
Revenue growth 5Y14.81%
Revenue growth Q2Q0.62%
3.2 Future
Based on estimates for the next years, BMY will show a decrease in Earnings Per Share. The EPS will decrease by -1.08% on average per year.
The Revenue is expected to decrease by -1.43% on average over the next years.
EPS Next Y-8%
EPS Next 2Y-2.22%
EPS Next 3Y-4.14%
EPS Next 5Y-1.08%
Revenue Next Year2.83%
Revenue Next 2Y1.88%
Revenue Next 3Y-0.3%
Revenue Next 5Y-1.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.55 indicates a rather cheap valuation of BMY.
Based on the Price/Earnings ratio, BMY is valued cheaper than 94.87% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.95, BMY is valued rather cheaply.
BMY is valuated cheaply with a Price/Forward Earnings ratio of 7.12.
Based on the Price/Forward Earnings ratio, BMY is valued cheaper than 95.38% of the companies in the same industry.
BMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.55 | ||
| Fwd PE | 7.12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMY indicates a rather cheap valuation: BMY is cheaper than 95.38% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMY indicates a rather cheap valuation: BMY is cheaper than 92.82% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.87 | ||
| EV/EBITDA | 6.09 |
4.3 Compensation for Growth
The decent profitability rating of BMY may justify a higher PE ratio.
BMY's earnings are expected to decrease with -4.14% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.48
EPS Next 2Y-2.22%
EPS Next 3Y-4.14%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.97%, BMY is a good candidate for dividend investing.
BMY's Dividend Yield is rather good when compared to the industry average which is at 4.46. BMY pays more dividend than 97.44% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.45, BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.97% |
5.2 History
On average, the dividend of BMY grows each year by 7.57%, which is quite nice.
BMY has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of BMY decreased in the last 3 years.
Dividend Growth(5Y)7.57%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
59.12% of the earnings are spent on dividend by BMY. This is a bit on the high side, but may be sustainable.
BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP59.12%
EPS Next 2Y-2.22%
EPS Next 3Y-4.14%
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (4/22/2024, 7:04:00 PM)
After market: 49.21 +0.07 (+0.14%)49.14
+0.21 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap99.59B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.97% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.55 | ||
| Fwd PE | 7.12 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.43% | ||
| ROE | 27.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 24.11% | ||
| PM (TTM) | 17.83% | ||
| GM | 76.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.86%
EPS 3Y5.21%
EPS 5Y
EPS growth Q2Q
EPS Next Y-8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y1.91%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y